Private Bancorp of America GAAP EPS of $1.97 misses by $0.10, revenue of $35.5M beats by $0.43M (NASDAQ:PBAM)

Private Bancorp of America reported Q3 GAAP EPS of $1.97, missing estimates by $0.10, while revenue of $35.5M exceeded expectations by $0.43M, up 12.7% year-over-year, according to the company.

Original reporting
Published Oct 16, 2026, 4:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 4:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PBAM
Neutral
medium confidence
Mentioned
$PBAM
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PBAMNeutralMed
01

Why it matters

Traders can reassess near-term expectations for earnings power versus revenue growth, but the excerpt lacks guidance and balance-sheet/credit details that often determine the magnitude of the post-earnings move.

02

Market read

A reported EPS miss alongside a revenue beat is a direct input to valuation and near-term positioning for PBAM.

03

What to watch

The brief does not include guidance, margin drivers, credit quality, or expense trends, which are usually decisive for follow-through after an EPS miss.

Relevance 8/10Novelty 8/10Timing: after-hours/earnings release timing (published 2026-10-16 16:28 UTC)

Background

The piece is a Seeking Alpha earnings-style summary of Private Bancorp of America’s Q3 results.

Company-level read

Ticker impact

$PBAMNeutralMedium confidence
Context

Private Bancorp of America reported Q3 GAAP EPS of $1.97, missing by $0.10, while revenue of $35.5M beat by $0.43M.

Expected impact

Shares may face mild pressure on the EPS miss, but the revenue beat could cushion selling as traders weigh operating leverage.

Evidence & confidence

The article provides the company’s own quarterly EPS and revenue beat/miss magnitudes, which typically drive immediate repricing and guidance expectations.

Market effects

Adds another datapoint on community banking earnings quality versus top-line growth.

No specific regional read-through provided beyond general banking sentiment.

Limited, company-specific earnings print with no cross-border catalyst mentioned.

Counterpoint

If investors focus on the revenue beat and interpret the EPS miss as temporary (timing, one-offs), the stock could outperform despite the headline miss.

Key entities

  • Private Bancorp of America

    Community bank reporting Q3 GAAP EPS and revenue versus estimates.

Related articles

$PBAMMed

Private Bancorp of America, Inc. Announces Strong Net Income for Third Quarter 2026

Private Bancorp of America, Inc. (PBAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Private Bancorp of America, Inc. Announces Strong Net Income for Third Quarter 2026 Third Quarter 2026 Highlights • Net income for the third quarter of 2026 was $11.4 million, compared to $13.1 million in the prior quarter and $9.7 million in th

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

HighAI 8/10

Merck KGaA Earnings Call Signals Stronger Growth Ahead

Merck KGaA (MKKGY) reported Q3 earnings with accelerated growth, raised full-year guidance, and announced strategic investments. Key highlights include 5.1% organic sales growth, EUR 1.66B operating cash flow, and plans to acquire Silence Therapeutics. Management emphasized growth in biomanufacturing, semiconductors, and rare diseases, while noting Mavenclad's declining sales and softer demand in consumer electronics.